department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Pemazyre · pharmadog

pharmadog
drugs
Pemazyre

drug · small molecule

patient view →

pemigatinib

Marketedupdated 2mo ago

by $INCY INCYTE CORP🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 11 investigational indications.

targets

Fibroblast growth factor receptor 3Fibroblast growth factor receptor 1Fibroblast growth factor receptor 2

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Pemazyre

trade names

Pemazyre

generic

pemigatinib

MOA

Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor

indication

Metastatic Bile Duct Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 17, 2027

284 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Oct 3, 2040compositionUS 12552792
Oct 3, 2040compositionUS 12552792
Oct 3, 2040compositionUS 12552792
Aug 30, 2040method-of-use (U-3571)US 11628162
Aug 30, 2040method-of-use (U-3571)US 11628162
Aug 30, 2040method-of-use (U-3571)US 11628162
May 3, 2039method-of-use (U-3466)US 11466004
May 3, 2039method-of-use (U-3466)US 11466004
May 3, 2039method-of-use (U-3466)US 11466004
Jan 30, 2035compositionUS 9611267
Jan 30, 2035compositionUS 9611267
Jan 30, 2035compositionUS 9611267
Apr 17, 2034method-of-use (U-2809)US 10131667
Apr 17, 2034method-of-use (U-2809)US 10131667
Apr 17, 2034method-of-use (U-2809)US 10131667

FDA exclusivities (6)

Aug 26, 2029ODE-404Orphan Drug (7y)3.1y
Aug 26, 2029ODE-404Orphan Drug (7y)3.1y
Aug 26, 2029ODE-404Orphan Drug (7y)3.1y
Apr 17, 2027ODE-292Orphan Drug (7y)284d
Apr 17, 2027ODE-292Orphan Drug (7y)284d
Apr 17, 2027ODE-292Orphan Drug (7y)284d

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying pemigatinib

phase2PH 2 Pemigatinib in SDH-deficient GISTrecruitingn=24
phase2A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangementrecruitingn=38
phase2A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterationsrecruitingn=40
phase1Pemigatinib + Afatinib in Advanced Refractory Solid Tumorsrecruitingn=70
phase2Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusionrecruitingn=25
phase2Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterationsterminatedn=83
phase1Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemiarecruitingn=32
phase2Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.active not recruitingn=206

more trials →